Kah-Lin Choo Singapore

Dr Kah Lin Choo is a Consultant at Department of Medicine, and Coordinator of Clinical Services at North District Hospital, Hong Kong. She is also an honorary Clinical Associate Professor at Chinese University of Hong Kong, the Head-Elect of Asian Pacific Society of Respirology (APSR) Sleep and Neurobiology Assembly, the past President of Hong Kong Society of Sleep Medicine, an Executive Board Member of Hong Kong Lung Foundation and an Executive Committee member of CHEST (Hong Kong and Macau Delegation). Dr Choo graduated from University of Nottingham, United Kingdom, in 1990. She underwent Respiratory Medicine, Advanced Internal Medicine and Critical Care Medicine training at Pamela Youde Nethersole Eastern Hospital and North District Hospital respectively. After receiving training in Sleep Medicine at Stanford University Sleep Disorders Center under Professor Guilleminault in 1996-97, she set up sleep services at Pamela Youde Nethersole Eastern Hospital in 1997 and North District Hospital in 2001. Since 2023, she has been the coordinator of a Hong Kong-wide high volume sleep service at Central Government Aided Emergency Hospital. Dr. Choo is a Fellow of Hong Kong College of Physicians, Hong Kong Academy of Medicine, APSR, Royal College of Physicians, Royal College of Physicians of Edinburgh, Royal College of Physicians and Surgeons of Glasgow and American College of Chest Physicians. She has served as a reviewer for Hong Kong Medical Journal and Respirology.
Job Title
Consultant
Faculty / Department / Division
Department of Medicine
Institution / Organisation
North District Hospital

19 November 2026, Thursday

Time Session
08:30
13:00
Naricha Chirakalwasan Chairperson Thailand
Rashidah Yasin Chairperson Malaysia
Function Room 8, Ground Mezzanine Floor

20 November 2026, Friday

Time Session
09:30
11:00
  • Ahmad Izuanuddin Ismail Chairperson Malaysia
  • David Halpin Speaker United Kingdom
  • Antonio Anzueto Speaker United States
  • Wisia Wedzicha Speaker United Kingdom
    This presentation will review aspects of COPD exacerbation management in the GOLD 2027 report.
  • Pang Yong Kek Speaker Malaysia
    Title: Leveraging Digital Tools in COPD Management for 2027 & Beyond Routine outpatient management of COPD faces a double deficit: up to 70% of patients make critical inhaler errors, with real-world adherence below 50%, whilst fewer than 3% complete centre-based pulmonary rehabilitation (PR). Digital healthcare addresses this through two synergistic pillars: connected smart inhalers—which enhance adherence by 22%–35% and reduce exacerbations by 17%–30% via objective flow and technique tracking—and digital therapeutics like myCOPD and Kaia COPD, which improve exercise capacity (+57.68 m 6MWD) with outcomes non-inferior to in-person PR. Remote Therapeutic Monitoring (RTM) billing frameworks establish clinical and financial viability by reimbursing multidisciplinary management of non-physiological data, medication adherence, and patient-reported outcomes. Looking toward 2027, multi-modal data fusion—integrating wearable vitals, acoustic cough biomarkers, and smart inhaler actuations—enables machine learning algorithms to forecast acute exacerbations up to 7 days ahead with 92% accuracy, aligning with recent GOLD strategy updates on early phenotypes (Pre-COPD/PRISm) and AI integration. Crucially, digital tools fail in isolation: patient engagement drops to 20% without supervision but exceeds 85% within a structured "clinician-in-the-loop" model, proving human clinical oversight remains essential for successful digital transformation.
  • Ahmad Izuanuddin Ismail Chairperson Malaysia
    Pang Yong Kek Chairperson Malaysia
Ballroom 1, Lower Ground Floor
Moo Suk Park Chairperson Republic of Korea
Noorul Afidza Muhammad Chairperson Malaysia
  • Ganesh Raghu Speaker United States
  • Jin Woo Song Speaker Republic of Korea
    Interstitial lung abnormalities (ILAs) are chest CT findings suggestive of interstitial lung disease (ILD) in people without a clinical diagnosis of ILD. With lung cancer screening and the wide use of CT, they are increasingly encountered in respiratory practice. The 2025 American Thoracic Society (ATS) clinical statement updated the 2020 Fleischner Society definition: ILA is now defined as bilateral, nondependent ground-glass or reticular abnormalities, lung distortion, traction bronchiectasis, or honeycombing involving at least 5% of a lung zone, without the requirement that the findings be incidental, and with high-risk groups such as familial pulmonary fibrosis and connective tissue disease included. A working definition separates ILA from ILD on the basis of symptoms, physiology, imaging, and pathology. ILA is found in about 3–10% of older adults and 4–17% of smokers. Risk factors include older age, male sex, smoking, occupational and environmental exposures, the MUC5B promoter variant, short telomeres, and a family history of pulmonary fibrosis. ILA is associated with respiratory symptoms, reduced exercise capacity, lung cancer, complications of cancer treatment and surgery, acute respiratory distress syndrome, and all-cause mortality. About half of ILAs progress radiologically, and subpleural fibrotic ILA, reticulation, and traction bronchiectasis carry the highest risk of progression and death. Based on 11 questions, the ATS statement suggests systematic assessment of ILA on lung cancer screening CT, baseline CT for adults with connective tissue disease at risk of ILD and for first-degree relatives older than 50 years in familial pulmonary fibrosis, assessment of symptoms and lung function at baseline, and serial CT timed by risk; it suggests against lung biopsy and routine MUC5B or telomere testing. Risk reduction, including smoking cessation and exposure remediation, is recommended throughout. No pharmacological treatment is currently recommended for ILA, but prevention trials with better-tolerated antifibrotics, such as DROP-FPF with nerandomilast, have begun. This lecture reviews the definition, epidemiology, clinical significance, risk assessment, and management of ILA, with data from Korean cohorts.
  • Yasuhiko Nishioka Speaker Japan
  • Q&A
Ballroom 4, Lower Ground Floor
11:00
12:00
David Lam Chi-Leung Chairperson Hong Kong
Ernest Mau Ern Poh Chairperson Malaysia
  • Ren Yuan Speaker Canada
    AI Radiomics for the Early Detection of Lung Cancer Background: Lung cancer remains the leading cause of cancer-related mortality in Canada. Low-dose computed tomography (LDCT) screening frequently detects small or ground-glass opacity nodules that are challenging to assess for malignancy. This study aimed to develop a radiomics-based machine-learning model to predict the future malignant behaviour of these difficult nodules. Materials and Methods: Small nodules were drawn from three lung cancer screening datasets: PanCan (n=2,085 participants; N=10,381 nodules), ILST (n=1,082 participants; N=2,389 nodules), and DLCS (n=1,373 participants; N=2,009 nodules). A self-attention deep-learning model was trained for nodule segmentation, and axial masks were reconstructed into three-dimensional core nodule masks. Radiomics features were extracted from four discrete regions: the nodule core and surrounding regions, including core-plus-edge, shell, and shell-without-blood-vessel masks. Machine-learning models were developed and compared with the Brock model. Results: At a low false-positive rate of 10%, the ML-radiomics models demonstrated superior sensitivity to the Brock model across all nodule types in the external validation set. Both approaches identified malignant nodules at baseline that would not have otherwise received interventional management and predicted malignancy up to 2 years before clinical confirmation. Conclusion: A pipeline integrating deep-learning segmentation with ML-radiomics can accurately classify subcentimetre nodules up to approximately 2 years before clinical confirmation of malignancy in lung cancer screening. Keywords: Lung Cancer, LDCT Screening, Radiomics, Machine Learning, Deep Learning
  • Chong Kin Liam Speaker Malaysia
    Lung cancer is a major health problem in the in the Asia-Pacific, with the region accounting for over 60% of global lung cancer diagnoses and deaths. Compared to Western counterparts, lung cancer in Asia exhibits distinct and unique characteristics. Key differences between lung cancer in Asia and outside Asia include a much higher prevalence in never-smokers, younger age of onset, and significantly higher rates of EGFR mutations (30-40% vs. 7-15% in the West). Over 30% of Asian lung cancer patients are never-smokers, with that number rising to over 50% in East Asian women. This is significantly higher than in Western countries. Asian patients have a much higher prevalence of EGFR mutations (30-40%) compared to Caucasian patients (7-15%). Conversely, KRAS mutations which are commonly smoking-related are less frequent in Asian patients (8-10%) than in Western populations (20-30%). While smoking is still a major cause, especially in men (half of the world's smokers live in Asia), never-smoker cases are highly driven by indoor air pollution (biomass fuel), ambient particulate matter (PM2.5), and passive smoking. Asian patients are generally diagnosed at a younger age, with early-onset lung cancer incidents rising, particularly in China, India, and Indonesia. Adenocarcinoma is the most common histological subtype in Asia, often appearing as ground-glass opacities. Asian patients tend to have a better prognosis. However, access to molecular diagnostics and newer, more effective treatments varies significantly between high-income countries (e.g., Japan, South Korea, Australia) and low-to-middle-income countries in the region.
  • Yuh-Min Chen Speaker Taiwan
    "Background Lung cancer is the leading cause of cancer-related mortality in the Asia Pacific (APAC) region, accounting for approximately 60% of global cases. The demographic of lung cancer in this region is shifting, with increasing incidence among younger individuals, non-smokers, and women. Driven by diverse risk factors including air pollution, occupational hazards, genetic predisposition, and household cooking fumes, there is a pressing need for personalized approaches to screening, diagnosis, and treatment. Early Detection & Screening Low-dose computed tomography (LDCT) screening has been instrumental in shifting detection toward early-stage disease. While global trials primarily focus on heavy smokers, regional data indicates that genetic factors play a critical role. A nationwide screening program in Taiwan demonstrated that individuals with a family history of lung cancer have a higher detection rate of early-stage disease (89.6%) compared to heavy smokers (66.1%). This targeted screening approach has led to a significant stage shift and a projected 53% reduction in lung cancer mortality. Targeted Therapy & Immunotherapy Recent phase III trials evaluating targeted therapies (such as osimertinib, amivantamab plus lazertinib, and lorlatinib) and immunotherapies (including pembrolizumab and neoadjuvant nivolumab) show that clinical efficacy and toxicity profiles in Asian cohorts are highly consistent with global populations. Subgroup analyses from landmark trials, including FLAURA2, MARIPOSA, KEYNOTE-189, and CheckMate 816, confirm that APAC patients derive comparable progression-free survival (PFS), overall survival (OS), and pathological complete response (pCR) benefits from these advanced treatment modalities. Conclusions & Future Challenges Despite the biological efficacy of advanced treatments mirroring global outcomes, the APAC region faces unique, systemic challenges. Wide regional variations in healthcare infrastructure, drug pricing, and reimbursement criteria—along with underrepresentation in global clinical trials—create significant disparities in early diagnosis and treatment access. Overcoming these socio-economic barriers and optimizing management strategies in resource-limited settings remain the primary challenges for improving lung cancer survival rates across the Asia Pacific region. "
  • Q&A
Ballroom 3, Lower Ground Floor
14:00
15:00
Brendon Yee Chairperson Australia
Rozanah Abdul Rahman Chairperson Malaysia
  • Ahmad Izuanuddin Ismail Speaker Malaysia
    "Obesity and obstructive sleep apnoea (OSA) are often approached as separate clinical problems: obesity as excess weight and OSA as upper-airway obstruction. This conventional framework, however, fails to capture the complex bidirectional relationship between adiposity, sleep-disordered breathing and cardiometabolic disease. Obesity is a chronic, relapsing disease characterised by dysfunctional adipose tissue, visceral and ectopic fat accumulation, inflammation, insulin resistance and altered neuroendocrine signalling. These processes can substantially influence respiratory mechanics, upper-airway collapsibility and ventilatory control, contributing to the development and progression of OSA. Conversely, untreated OSA produces recurrent intermittent hypoxia, sleep fragmentation and sympathetic activation, promoting oxidative stress, endothelial dysfunction, hypertension, insulin resistance and broader cardiometabolic consequences. The interaction between obesity and OSA therefore creates a self-reinforcing cycle that extends far beyond the airway. This presentation explores the pathophysiological continuum linking obesity, OSA and cardiometabolic disease, and considers its implications for public health. Traditional treatment strategies, including lifestyle intervention, positive airway pressure and metabolic/bariatric surgery, remain fundamental. However, emerging pharmacological therapies offer an opportunity to address upstream biological drivers of disease. In particular, GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists represent an important evolution in obesity management, with emerging evidence demonstrating improvements in OSA severity and cardiometabolic risk alongside substantial weight reduction. The future of sleep medicine may therefore lie beyond treating airway obstruction alone. A personalised, integrated approach—combining airway therapy, obesity treatment, lifestyle intervention and cardiometabolic risk reduction—offers an opportunity to treat the patient rather than simply the apnoea. Obesity is more than a weight issue, and OSA is more than an airway problem. "
  • Yizhong Zheng Speaker Australia
    The Asia-Pacific now carries the world’s largest burden of obesity, yet obesity hypoventilation syndrome (OHS) remains under-recognised and often presents late, with acute respiratory failure. This talk examines whether current diagnostic criteria and screening tools, largely derived from non-Asian populations, serve our patients well. It explores why Asian patients may develop OHS at a lower BMI, how to identify them earlier, and how to choose and optimise PAP therapy. Finally, it considers where bariatric surgery and the new incretin-based therapies fit in a disease that PAP alone does not cure.
  • Brendon Yee Speaker Australia
    "Obstructive sleep apnoea (OSA) affects an estimated one billion adults worldwide, most of whom are overweight or obese. Yet care remains largely mechanical: diagnose, prescribe positive airway pressure (PAP), advise weight loss, and judge success by device-reported AHI. Weight-loss advice is rarely structured or followed up, and PAP, while controlling AHI and symptoms, has not been shown to alter cardiometabolic trajectory. This presentation argues for a shift in the sleep physician's role. Weight loss is disease-modifying: a 20% BMI reduction is associated with an approximately 57% fall in AHI, acting chiefly on pharyngeal collapsibility, the dominant OSA endotype. In SURMOUNT-OSA, tirzepatide reduced AHI by 20–24 events/h versus placebo over 52 weeks, with or without PAP, alongside improvements in hypoxic burden, sleepiness, blood pressure, hsCRP and patient-reported outcomes. Mediation analyses show these cardiometabolic benefits are driven predominantly by weight loss, with AHI and hypoxic-burden reduction independently mediating selected outcomes. Meta-analytic and real-world data support a class effect. A practical model of care is then outlined: patient selection, clinical and financial consent, monitoring for gastrointestinal effects, lean-mass loss and weight regain, and multidisciplinary co-management with primary care, dietetics, exercise physiology and psychology. Incretin therapy is positioned as complementary to PAP, not a replacement. Finally, Asia-Pacific realities are addressed, including variable approval and reimbursement, out-of-pocket costs, and growing cosmetic and grey-market GLP-1 use, underscoring why sleep physicians must own the medical narrative."
  • Q&A
Ballroom 3, Lower Ground Floor

21 November 2026, Saturday

Time Session
11:00
12:30
Allen Widysanto Chairperson Indonesia
Rashidah Yasin Chairperson Malaysia
  • Naricha Chirakalwasan Speaker Thailand
  • Kah-Lin Choo Speaker Singapore
    Toward Personalised Non-PAP Therapy for Obstructive Sleep Apnoea While positive airway pressure (PAP) remains the gold standard treatment for obstructive sleep apnoea (OSA), long-term compliance is frequently limited by patient intolerance. Emerging insights into the pathophysiology of OSA reveal that the condition is not solely driven by anatomical airway collapse; rather, it is governed by four distinct endotypes that include three non-anatomical endotypes such as poor upper airway muscle responsiveness, low respiratory arousal threshold, and high loop gain (ventilatory control instability). This paradigm shift paves the way for precision medicine and targeted, non-PAP therapeutic strategies tailored to individual physiological profiles. This lecture will review recent advances in non-PAP therapeutic modalities mapped to specific OSA endotypes, examine clinical trial evidence, and address current challenges and future directions in clinical phenotyping and personalized care. Strategies include anti-obesity interventions such as dual GIP/GLP-1 receptor agonists and structural stabilization through hypoglossal or ansa cervicalis nerve stimulation, pharmacological neuromuscular stabilization, loop gain modulation and arousal threshold management. Personalising non-PAP therapy based on individual pathophysiological traits offers a promising paradigm for patients who refuse or are intolerant to PAP. Future clinical success relies on validating automated computational phenotyping tools within routine diagnostic workflows, standardizing prediction thresholds across diverse global populations, and establishing outcome-focused trials linked to hard clinical endpoint.
  • Winfried J. Randerath Speaker Germany
  • Q&A
Ballroom 2, Lower Ground Floor
14:00
15:30
Amila Rathnapala Chairperson Sri Lanka
Gin Tsen Chai Chairperson Singapore
  • Marissa O'Callaghan Speaker Ireland
    Pulmonary alveolar proteinosis (PAP) is a rare but treatable cause of respiratory impairment that presents important diagnostic and therapeutic challenges. Using a case-based approach, this presentation will explore when to suspect PAP, how to confirm the diagnosis and distinguish its underlying causes, and when to consider treatment. It will highlight the roles of bronchoalveolar lavage and GM-CSF autoantibody testing, alongside practical approaches to assessing disease severity and progression. Established and emerging treatments, including whole-lung lavage and inhaled GM-CSF, will be discussed. Attendees will gain a practical framework for recognising PAP, initiating appropriate investigations and identifying patients who would benefit from specialist referral.
  • Moo Suk Park Speaker Republic of Korea
  • Q&A
Ballroom 3, Lower Ground Floor